Pasithea Therapeutics Corp. (KTTAW)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
📈 **POSITIVE** • Low confidence analysis (54%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (82%) **Content type:** Clinical